Continuing Education Activity

Primary amebic meningoencephalitis (PAM) represents a rare, fulminant infection of the central nervous system caused by the thermophilic, free-living ameba Naegleria fowleri. Predominantly affecting previously healthy children and young adults, PAM progresses rapidly, with early nonspecific symptoms often mimicking bacterial meningitis. This course outlines the pathophysiologic transmission of this disease, which results from trophozoites entering the nasal cavity via warm freshwater exposure, invading the olfactory mucosa, and causing intense cerebral inflammation, necrosis, and edema, and its clinical course, involving rapid neurologic deterioration, seizures, and increased intracranial pressure, which frequently leads to death within days.

This course reviews the diagnostic evaluation of PAM, which relies on prompt cerebrospinal fluid analysis, wet mount visualization, and nucleic acid amplification testing, while neuroimaging provides supportive but nonspecific findings. Participants will also gain an understanding of the optimal management of this condition, involving early, aggressive combination therapy with amoebicidal agents, intensive neurocritical care, and interprofessional consultation. This activity for healthcare professionals is designed to enhance learners' competence in identifying PAM, performing the recommended evaluation, and implementing an appropriate interprofessional approach when managing this high-mortality condition, ultimately improving patient outcomes.

Objectives:

• Identify early clinical features suggestive of primary amebic meningoencephalitis to prompt timely diagnostic evaluation.
• Differentiate the diagnostic features of primary amebic meningoencephalitis from other causes of acute meningitis.
• Implement evidence-informed management strategies for primary amebic meningoencephalitis caused by Naegleria fowleri.
• Collaborate effectively within an interprofessional healthcare team to improve care coordination and outcomes for patients with primary amebic meningoencephalitis.

Access free multiple choice questions on this topic.

Introduction

Primary amebic meningoencephalitis (PAM) is a rare, rapidly progressive infection of the central nervous system caused by the free-living ameba Naegleria fowleri, commonly known as the “brain-eating ameba.” Naegleria fowleri is a eukaryotic, free-living ameba and is 1 of 4 free-living amebae known to cause human disease. The other pathogenic free-living amebae—Acanthamoeba spp., Balamuthia mandrillaris, and Sappinia spp.—are also associated with severe infections of the central nervous system, including granulomatous amebic encephalitis.[1][2][3]

PAM disease is characterized by acute inflammation and necrosis of brain tissue, leading to severe cerebral edema, herniation, and death in most affected individuals. It primarily affects previously healthy children and young adults and progresses rapidly. Early symptoms are nonspecific and often mimic acute bacterial meningitis, contributing to delays in diagnosis and treatment.[3] Despite advances in diagnostic testing and antimicrobial therapy, PAM remains associated with an extremely high case-fatality rate. Increased clinician awareness, early recognition, and prompt initiation of therapy are essential to improving survival.[4][5][6]

Etiology

PAM is caused by Naegleria fowleri, a thermophilic, free-living ameba that thrives in warm freshwater environments. The organism proliferates at temperatures above 30 °C and can tolerate temperatures up to 45 °C, but does not survive in saltwater. N fowleri is a facultative parasite, meaning it does not require a human host to complete its life cycle and reproduces asexually by mitosis. Of the 47 recognized species within the genus Naegleria, only N fowleri is known to cause PAM.[2]

Naegleria fowleri exists in 3 morphologic forms: trophozoite, flagellate, and cyst. The trophozoite is the infective, replicative, and invasive stage responsible for human disease. Under unfavorable environmental conditions, trophozoites may transform into flagellates by developing flagella, enabling temporary motility in low-nutrient environments. With continued adverse conditions, the organism encysts, forming metabolically inactive cysts measuring approximately 7 to 12 µm in diameter. These cysts are highly resistant to environmental stressors, including low temperatures, and enable survival during colder months.[7]

Trophozoites are elongated, typically measuring approximately 22 µm in length, and possess pseudopodia that facilitate movement and ingestion of bacteria and fungi in warm freshwater. As a thermophilic organism, N fowleri is most active during the summer months, when human exposure is more likely. During colder periods, trophozoites may encyst and settle into sediment until environmental conditions become favorable again.[7]

Epidemiology

Naegleria fowleri is distributed worldwide and is commonly found in soil and warm freshwater environments, including lakes, rivers, ponds, hot springs, and inadequately chlorinated swimming pools. The organism has also been identified in man-made water systems, eg, water heaters, splash pads, and household tap water.[8] Globally, 39 countries, including the United States, are reporting increasing numbers of cases; outside of the United States, Pakistan, India, Australia, Mexico, and the Czech Republic report the highest number of cases, possibly due to their year-round warmer climates and freshwater bodies that easily support the growth and replication of N fowleri.[4] 

In 2023, Pakistan emerged as a hot spot for infections with 147 documented cases, centered on Karachi and the surrounding areas. Increased monsoon activity with flooding, and inadequate chlorination of municipal water supplies were cited as potential reasons for the increase.[9] For comparison, the United States had 167 cases reported nationwide from 1962 to 2024, with most infections centered in southern states. However, farther north, cases have appeared in Minnesota, Kansas, and Indiana, likely due to global warming and the resulting expansion of pathogen distribution.[4] In 2020 and 2021, 2 young children acquired N fowleri infection after exposure at a splash pad, highlighting the potential risk associated with inadequately disinfected recreational water features.[10][CDC. Operating and Managing Public Pools, Hot Tubs and Splash Pads. 2025] Nasal irrigation or ritual nasal rinsing performed with untreated tap water was cited for cases reported in Louisiana and the U.S. Virgin Islands.[4][5] 

Infections occur predominantly during warmer months, when water temperatures rise, and exposure during outdoor freshwater activities increases. Human infection occurs when water contaminated with N fowleri enters the nasal cavity, most commonly during swimming, diving, or nasal irrigation with untreated water. The organism then migrates along the olfactory nerve to the central nervous system. Infection does not occur through ingestion of contaminated water, and person-to-person transmission has not been reported.[4][5] PAM disproportionately affects children and adolescents and shows a marked male predominance. The mean age of affected patients is approximately 12 years, with reported cases ranging from 8 months to 66 years; nearly 80% of cases occur in males.

Survival remains exceedingly rare, with mortality rates of 95% to 99%. Worldwide, 10 to 15 survivors have been documented, with 4 in the United States. Early recognition and aggressive treatment are paramount to survival; N fowleri remains an emerging global health concern, particularly in light of global warming, which can expand the pathogen's distribution worldwide.[9]

Pathophysiology

PAM occurs following the introduction of warm freshwater contaminated with Naegleria fowleri into the nose. Trophozoites then penetrate the olfactory mucosa, migrate along the olfactory nerves, cross the cribriform plate, and reach the olfactory bulbs of the brain. Once within the central nervous system, the ameba induces intense inflammation, direct cytotoxic injury, and hemorrhagic necrosis of brain tissue.[9]

Within the brain parenchyma, N fowleri induces severe necrotizing and hemorrhagic inflammation through a combination of direct cytotoxicity and host immune activation. The trophozoites possess surface structures that facilitate contact-dependent cytolysis and phagocytosis of neural tissue, accompanied by the release of tissue-destructive enzymes, including acid hydrolases, phospholipases, neuraminidases, and other cytolytic proteases. These mediators disrupt host cell membranes and contribute to rapid neuronal and glial destruction.[11][12]

Tissue injury is further amplified by the innate immune response, particularly activation of the complement cascade and recruitment of neutrophils and macrophages, leading to intense inflammatory edema. The resulting cerebral swelling causes increased intracranial pressure and reduced cerebral perfusion.[9][12] Rapid disease progression leads to altered mental status, seizures, brain herniation, and death, often within a week of symptom onset.[4]

Histopathology

Naegleria fowleri has a 3-stage life cycle: amoeboid trophozoites, flagellate, and cysts. Hostile environmental changes can cause the trophozoites to change to the flagellated form, and the parasite will revert when conditions improve. Naegleria fowleri trophozoites are found in cerebrospinal fluid (CSF) and tissue, and occasionally, flagellated forms may be noted in the CSF. Cysts are not seen in brain tissue.[13][CDC. Free Living Amebic Infections. 2024]

History and Physical

Patients with PAM typically present with an acute, rapidly progressive meningoencephalitis. Early manifestations are nonspecific and often resemble acute bacterial meningitis. Common presenting symptoms include high fever, severe frontal or temporal headache, nausea, vomiting, photophobia, and malaise. Olfactory or gustatory disturbances may occur early in the disease course and are thought to reflect invasion of the olfactory mucosa.[4]

Symptom onset usually occurs within several days of freshwater exposure, most commonly between 2 and 8 days. However, cases have been reported as early as 24 hours and as late as 1 to 2 weeks after exposure. As the disease progresses, neurologic deterioration is rapid, with the development of confusion, agitation, seizures, and a declining level of consciousness, frequently progressing to coma.[4]

On physical examination, patients typically exhibit signs of meningeal irritation, including neck stiffness and positive Kernig and Brudzinski signs. Cranial nerve palsies and focal neurologic deficits may emerge as cerebral edema and intracranial pressure increase. Markedly elevated intracranial pressure can lead to uncal herniation and death. Cardiac complications, including arrhythmias and myocardial injury, have been reported in some cases.[4]

Evaluation

Lumbar puncture with CSF analysis is the cornerstone of diagnostic evaluation for PAM. Peripheral laboratory testing frequently demonstrates leukocytosis with neutrophil predominance. CSF analysis typically reveals markedly elevated opening pressure, often far exceeding normal values. The CSF appearance may be cloudy or gray early in the course and may become hemorrhagic as the disease progresses. Characteristic findings include a very high white blood cell count (often 300 to >20,000 cells/mm³) with neutrophilic predominance, elevated protein concentration, hypoglycorrhachia, and the presence of red blood cells. Gram stain and routine bacterial cultures are usually negative.[4]

Direct microscopic examination of fresh, unrefrigerated CSF using a wet mount preparation can demonstrate motile Naegleria fowleri trophozoites and remains a critical early diagnostic step. Because trophozoites rapidly lose motility with refrigeration or delayed processing, immediate examination after lumbar puncture is essential. Concentration techniques, including cytospin preparations, followed by Wright–Giemsa, Giemsa, hematoxylin and eosin, or modified trichrome staining, may enhance detection. Gram staining should be avoided, as heat fixation can destroy the organisms.[14][4]

Definitive diagnosis is established by nucleic acid amplification testing. Polymerase chain reaction (PCR) assays targeting N fowleri ribosomal gene sequences are considered the diagnostic gold standard and are available through specialized reference laboratories, including the Centers for Disease Control and Prevention (CDC). Immunohistochemical and indirect immunofluorescence assays using organism-specific antibodies may also identify N fowleri in CSF or tissue specimens, but are not widely available in routine clinical laboratories. When performed, a brain biopsy or autopsy can confirm the diagnosis through histopathologic identification of trophozoites.[15][4]

Neuroimaging findings are nonspecific but commonly demonstrate diffuse cerebral edema, meningeal enhancement, and frontal or temporal lobe involvement, reflecting the typical route of invasion along the olfactory pathways.[16] MRI may also demonstrate diffuse involvement of the midbrain and subarachnoid spaces.

Treatment / Management

The optimal therapeutic approach for PAM caused by Naegleria fowleri remains uncertain.[15] No randomized or comparative studies evaluating single-agent or combination regimens have been conducted, owing to the rarity of the disease, frequent diagnostic delays, and its fulminant clinical course. Consequently, current treatment strategies are based on in vitro susceptibility data, animal models, survivor case reports, and extrapolation from experience with other free-living amebae, including Acanthamoeba spp. and Balamuthia mandrillaris.[17][18]

Survivors of PAM have typically received early, aggressive combination therapy consisting of agents with demonstrated antiamebic activity and adequate central nervous system penetration, in conjunction with intensive neurocritical care to control cerebral edema and intracranial hypertension. In theory, the optimal regimen should include 1 or more amoebicidal drugs with favorable in vitro activity and the ability to cross the blood–brain barrier. Recent studies have identified emerging therapies that may be beneficial in the treatment of PAM.[19][20]

Based on published survivor cases and expert recommendations, combination therapy generally includes the following agents (see Table 1), in addition to corticosteroids for cerebral edema:

• Conventional amphotericin B (intravenous ± intrathecal):

  • Conventional amphotericin B is preferred over the liposomal formulation for both intrathecal and intravenous administration, as in vitro studies indicate a higher minimum inhibitory concentration (MIC) for the liposomal formulation than for conventional amphotericin B.[21]
• Rifampin
• Fluconazole or another azole antifungal
• Miltefosine [22][23]
• Azithromycin

The duration of therapy is not standardized, with reported courses ranging from approximately 9 to 30 days.

Given the complexity and rarity of PAM, early consultation with infectious diseases specialists and the CDC is strongly recommended to assist with diagnostic confirmation and therapeutic guidance.[CDC. Clinical Care of Naegleria fowleri Infection. 2025] Clinicians may reach the CDC Emergency Operations Center with the contact number 770-488-7100.

Table

Table 1. Drugs for Primary Amebic Meningoencephalitis.

Differential Diagnosis

The clinical presentation of PAM is very similar to that of acute bacterial meningitis, and CSF parameters are also similar. Therefore, obtaining an epidemiological history in patients with suspected bacterial meningitis who have negative cultures and fail to improve cannot be emphasized enough. The differential diagnosis of PAM includes bacterial brain abscesses, tuberculosis, Nocardia, Herpes simplex, CNS aspergillosis, cryptococcosis, and Histoplasma. Toxoplasmosis, cysticercosis, and CNS lymphoma should be considered.

Prognosis

PAM is associated with an extremely high mortality rate.[24] Studies have reported a case-fatality rate of as high as 99%. The mean time from onset of symptoms to death was 5.3 days (ranging from 1 to 12 days), and the mean time from exposure to death was 9.9 days (ranging from 6 to 17 days).

Complications

N fowleri infection causes PAM, which is a rapidly progressive and often fatal disease. The infection leads to severe cerebral edema, hemorrhagic necrosis, and increased intracranial pressure, which can result in brain herniation and death within days of symptom onset. Other complications include seizures, cranial nerve dysfunction, hydrocephalus, and coma.[6] Intact survivors are possible with rapid recognition and treatment, but rare; survivors often endure long-term complications from brain damage necessitating prolonged rehabilitation to recover basic skills.[18]

Consultations

Managing PAM requires an interprofessional approach. Specialists to consult include infectious disease physicians, neurologists, neuroradiologists, interventional radiologists, pharmacists, and intensivists.

Deterrence and Patient Education

Measures to prevent PAM due to Naegleria include the following:

• Avoid diving and jumping into stagnant freshwater.
• Consider using nose plugs for unavoidable exposures or pinching your nose shut when diving or swimming in freshwater.
• Keep your head above water when swimming in freshwater, hot springs, and other untreated thermal bodies of water.
• When participating in water-related activities, avoid digging or stirring up the sediment.
• Use boiled, filtered, or sterile water for nasal or sinus irrigation, not tap water.[8][4]

Pearls and Other Issues

Other important information to note includes the following:

• Patients with PAM typically have a history of swimming, diving, bathing, or playing in warm, generally stagnant freshwater during the previous 1 to 9 days.
• Nasal irrigartion with non sterile water, such as tap water, is also highly implicated in cases of N fowleri.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol. 2007 Jun;50(1):1-26. [PubMed: 17428307]

2.

Zhang H, Cheng X. Various brain-eating amoebae: the protozoa, the pathogenesis, and the disease. Front Med. 2021 Dec;15(6):842-866. [PubMed: 34825341]

3.

Kofman A, Guarner J. Infections Caused by Free-Living Amoebae. J Clin Microbiol. 2022 Jan 19;60(1):e0022821. [PMC free article: PMC8769735] [PubMed: 34133896]

4.

Gharpure R, Bliton J, Goodman A, Ali IKM, Yoder J, Cope JR. Epidemiology and Clinical Characteristics of Primary Amebic Meningoencephalitis Caused by Naegleria fowleri: A Global Review. Clin Infect Dis. 2021 Jul 01;73(1):e19-e27. [PMC free article: PMC8739754] [PubMed: 32369575]

5.

Yoder JS, Eddy BA, Visvesvara GS, Capewell L, Beach MJ. The epidemiology of primary amoebic meningoencephalitis in the USA, 1962-2008. Epidemiol Infect. 2010 Jul;138(7):968-75. [PubMed: 19845995]

6.

Matanock A, Mehal JM, Liu L, Blau DM, Cope JR. Estimation of Undiagnosed Naegleria fowleri Primary Amebic Meningoencephalitis, United States¹. Emerg Infect Dis. 2018 Jan;24(1):162-164. [PMC free article: PMC5749439] [PubMed: 29260676]

7.

Salazar-Ardiles C, Asserella-Rebollo L, Andrade DC. Free-Living Amoebas in Extreme Environments: The True Survival in our Planet. Biomed Res Int. 2022;2022:2359883. [PMC free article: PMC9596261] [PubMed: 36303587]

8.

Cope JR, Ali IK. Primary Amebic Meningoencephalitis: What Have We Learned in the Last 5 Years? Curr Infect Dis Rep. 2016 Sep;18(10):31. [PMC free article: PMC5100007] [PubMed: 27614893]

9.

Alanazi A, Younas S, Ejaz H, Alruwaili M, Alruwaili Y, Mazhari BBZ, Atif M, Junaid K. Advancing the understanding of Naegleria fowleri: Global epidemiology, phylogenetic analysis, and strategies to combat a deadly pathogen. J Infect Public Health. 2025 Apr;18(4):102690. [PubMed: 39913985]

10.

Miko S, Cope JR, Hlavsa MC, Ali IKM, Brown TW, Collins JP, Greeley RD, Kahler AM, Moore KO, Roundtree AV, Roy S, Sanders LL, Shah V, Stuteville HD, Mattioli MC. A Case of Primary Amebic Meningoencephalitis Associated with Surfing at an Artificial Surf Venue: Environmental Investigation. ACS ES T Water. 2023 Mar 15;3(4):1126-1133. [PMC free article: PMC10193442] [PubMed: 37213412]

11.

Kim JH, Sohn HJ, Shin HJ, Walz SE, Jung SY. Understanding the pathogenicity of Naegleria fowleri in association with N. fowleri antigen-1 (Nfa1). Parasites Hosts Dis. 2024 Nov;62(4):385-398. [PMC free article: PMC11614482] [PubMed: 39622651]

12.

Chen CW, Moseman EA. Pro-inflammatory cytokine responses to Naegleria fowleri infection. Front Trop Dis. 2022;3 [PMC free article: PMC10104475] [PubMed: 37065537]

13.

Evdokiou A, Marciano-Cabral F, Jamerson M. Studies on the cyst stage of Naegleria fowleri in vivo and in vitro. J Eukaryot Microbiol. 2022 Mar;69(2):e12881. [PubMed: 34918439]

14.

Capewell LG, Harris AM, Yoder JS, Cope JR, Eddy BA, Roy SL, Visvesvara GS, Fox LM, Beach MJ. Diagnosis, Clinical Course, and Treatment of Primary Amoebic Meningoencephalitis in the United States, 1937-2013. J Pediatric Infect Dis Soc. 2015 Dec;4(4):e68-75. [PubMed: 26582886]

15.

Haston JC, Cope JR. Amebic encephalitis and meningoencephalitis: an update on epidemiology, diagnostic methods, and treatment. Curr Opin Infect Dis. 2023 Jun 01;36(3):186-191. [PMC free article: PMC10798061] [PubMed: 37093056]

16.

Singh P, Kochhar R, Vashishta RK, Khandelwal N, Prabhakar S, Mohindra S, Singhi P. Amebic meningoencephalitis: spectrum of imaging findings. AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1217-21. [PMC free article: PMC8133936] [PubMed: 16775267]

17.

Bellini NK, Santos TM, da Silva MTA, Thiemann OH. The therapeutic strategies against Naegleria fowleri. Exp Parasitol. 2018 Apr;187:1-11. [PubMed: 29501696]

18.

Grace E, Asbill S, Virga K. Naegleria fowleri: pathogenesis, diagnosis, and treatment options. Antimicrob Agents Chemother. 2015 Nov;59(11):6677-81. [PMC free article: PMC4604384] [PubMed: 26259797]

19.

Fong H, Debnath A. The Activity of FDA-Approved Prodrug Isavuconazonium Sulfate and Its Major Metabolite Isavuconazole Against Naegleria fowleri. Pharmaceutics. 2026 Jan 12;18(1) [PMC free article: PMC12844783] [PubMed: 41599210]

20.

Chao-Pellicer J, Arberas-Jiménez I, Sifaoui I, Piñero JE, Lorenzo-Morales J. Exploring therapeutic approaches against Naegleria fowleri infections through the COVID box. Int J Parasitol Drugs Drug Resist. 2024 Aug;25:100545. [PMC free article: PMC11091526] [PubMed: 38718717]

21.

Cárdenas-Zúñiga R, Silva-Olivares A, Villalba-Magdaleno JA, Sánchez-Monroy V, Serrano-Luna J, Shibayama M. Amphotericin B induces apoptosis-like programmed cell death in Naegleria fowleri and Naegleria gruberi. Microbiology (Reading). 2017 Jul;163(7):940-949. [PubMed: 28721850]

22.

Centers for Disease Control and Prevention (CDC). Investigational drug available directly from CDC for the treatment of infections with free-living amebae. MMWR Morb Mortal Wkly Rep. 2013 Aug 23;62(33):666. [PMC free article: PMC4604798] [PubMed: 23965830]

23.

Alli A, Ortiz JF, Morillo Cox Á, Armas M, Orellana VA. Miltefosine: A Miracle Drug for Meningoencephalitis Caused by Free-Living Amoebas. Cureus. 2021 Mar 04;13(3):e13698. [PMC free article: PMC8020194] [PubMed: 33833918]

24.

Rehman SU, Farooq S, Tariq MB, Nasir N, Wasay M, Masood S, Karim M. Clinical manifestations and outcome of patients with primary amoebic meningoencephalitis in Pakistan. A single-center experience. PLoS One. 2023;18(11):e0290394. [PMC free article: PMC10631667] [PubMed: 37939056]

Disclosure: Vini Vijayan declares no relevant financial relationships with ineligible companies.

Disclosure: Debbie Tristram declares no relevant financial relationships with ineligible companies.

Disclosure: Vidya Sundareshan declares no relevant financial relationships with ineligible companies.